Cargando…

Transfusion-related acute lung injury; clinical perspectives

Transfusion-related acute lung injury (TRALI) was introduced in 1983 to describe a clinical syndrome seen within 6 h of a plasma-containing blood products transfusion. TRALI is a rare transfusion complication; however, the FDA has suggested that TRALI is the leading cause of transfusion-related mort...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jeongmin, Na, Sungwon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Anesthesiologists 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4384395/
https://www.ncbi.nlm.nih.gov/pubmed/25844126
http://dx.doi.org/10.4097/kjae.2015.68.2.101
_version_ 1782364897365983232
author Kim, Jeongmin
Na, Sungwon
author_facet Kim, Jeongmin
Na, Sungwon
author_sort Kim, Jeongmin
collection PubMed
description Transfusion-related acute lung injury (TRALI) was introduced in 1983 to describe a clinical syndrome seen within 6 h of a plasma-containing blood products transfusion. TRALI is a rare transfusion complication; however, the FDA has suggested that TRALI is the leading cause of transfusion-related mortality. Understanding the pathogenesis of TRALI will facilitate adopting preventive strategies, such as deferring high plasma volume female product donors. This review outlines the clinical features, pathogenesis, treatment, and prevention of TRALI.
format Online
Article
Text
id pubmed-4384395
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher The Korean Society of Anesthesiologists
record_format MEDLINE/PubMed
spelling pubmed-43843952015-04-03 Transfusion-related acute lung injury; clinical perspectives Kim, Jeongmin Na, Sungwon Korean J Anesthesiol Review Article Transfusion-related acute lung injury (TRALI) was introduced in 1983 to describe a clinical syndrome seen within 6 h of a plasma-containing blood products transfusion. TRALI is a rare transfusion complication; however, the FDA has suggested that TRALI is the leading cause of transfusion-related mortality. Understanding the pathogenesis of TRALI will facilitate adopting preventive strategies, such as deferring high plasma volume female product donors. This review outlines the clinical features, pathogenesis, treatment, and prevention of TRALI. The Korean Society of Anesthesiologists 2015-04 2015-03-30 /pmc/articles/PMC4384395/ /pubmed/25844126 http://dx.doi.org/10.4097/kjae.2015.68.2.101 Text en Copyright © the Korean Society of Anesthesiologists, 2015 http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Kim, Jeongmin
Na, Sungwon
Transfusion-related acute lung injury; clinical perspectives
title Transfusion-related acute lung injury; clinical perspectives
title_full Transfusion-related acute lung injury; clinical perspectives
title_fullStr Transfusion-related acute lung injury; clinical perspectives
title_full_unstemmed Transfusion-related acute lung injury; clinical perspectives
title_short Transfusion-related acute lung injury; clinical perspectives
title_sort transfusion-related acute lung injury; clinical perspectives
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4384395/
https://www.ncbi.nlm.nih.gov/pubmed/25844126
http://dx.doi.org/10.4097/kjae.2015.68.2.101
work_keys_str_mv AT kimjeongmin transfusionrelatedacutelunginjuryclinicalperspectives
AT nasungwon transfusionrelatedacutelunginjuryclinicalperspectives